Toll-like receptor 3, RIG-I-like receptors and the NLRP3 inflammasome: Key modulators of innate immune responses to double-stranded RNA viruses

Cytokine and Growth Factor Reviews

Volumn 22, Issue 2, 2011, Pages 63-72

  Yu, Man ^a   Levine, Stewart J ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Double stranded viral RNA; NLRP3 inflammasome; RIG I; Signal transduction; TLR3

Indexed keywords

ANTIVIRUS AGENT; CANCER VACCINE; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CRYOPYRIN; DENDRITIC CELL VACCINE; DOUBLE STRANDED RNA; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IBOCTADEKIN; INFLAMMASOME; INTERFERON; INTERLEUKIN 1BETA CONVERTING ENZYME INHIBITOR; POLYADENYLIC POLYURIDYLIC ACID; POLYI POLYC12U; POLYINOSINIC POLYCYTIDYLIC ACID; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RETINOIC ACID INDUCIBLE GENE 1 LIKE RECEPTOR; RETINOIC ACID INDUCIBLE PROTEIN I; RILONACEPT; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; VIRUS RNA; VRT 018858; CARRIER PROTEIN; DEAD BOX PROTEIN;

ACUTE HEART INFARCTION; ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ALLERGY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BIOLOGICAL ACTIVITY; BRAIN DAMAGE; BREAST CANCER; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; COMPLEX FORMATION; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; GLIOMA; GOUT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOREGULATION; INFECTION; INFECTION PREVENTION; INFLAMMATION; INFLUENZA A (H5N1); INNATE IMMUNITY; INTRACELLULAR SIGNALING; LIGAND BINDING; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOLECULAR RECOGNITION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN RNA BINDING; REVIEW; RHEUMATOID ARTHRITIS; RNA VIRUS; STROKE; TH1 CELL; TOROVIRUS INFECTION; TRANSIENT ISCHEMIC ATTACK; TRAUMATIC BRAIN INJURY; ANIMAL; IMMUNOLOGY; SIGNAL TRANSDUCTION;

RNA VIRUSES;

ANIMALS; CARRIER PROTEINS; DEAD-BOX RNA HELICASES; HUMANS; IMMUNITY, INNATE; INFLAMMASOMES; POLY I-C; RNA VIRUSES; RNA, DOUBLE-STRANDED; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 3;

EID: 79957784838     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2011.02.001     Document Type: Review

References (120)

1. Kanneganti T.D. Central roles of NLRs and inflammasomes in viral infection. Nat Rev Immunol 2010, 10:688-698.
2. Akira S., Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004, 4:499-511.
3. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004, 5:987-995.
4. Pulko V., Liu X., Krco C.J., Harris K.J., Frigola X., Kwon E.D., et al. TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination. J Immunol 2009, 183:3634-3641.
5. Matsumoto M., Funami K., Tanabe M., Oshiumi H., Shingai M., Seto Y., et al. Subcellular localization of Toll-like receptor 3 in human dendritic cells. J Immunol 2003, 171:3154-3162.
6. Lee H.K., Dunzendorfer S., Soldau K., Tobias P.S. Double-stranded RNA-mediated TLR3 activation is enhanced by CD14. Immunity 2006, 24:153-163.
7. Wang Y., Liu L., Davies D.R., Segal D.M. Dimerization of Toll-like receptor 3 (TLR3) is required for ligand binding. J Biol Chem 2010, 285:36836-36841.
8. Liu L., Botos I., Wang Y., Leonard J.N., Shiloach J., Segal D.M., et al. Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science 2008, 320:379-381.
9. Brinkmann M.M., Spooner E., Hoebe K., Beutler B., Ploegh H.L., Kim Y.M. The interaction between the ER membrane protein UNC93B and TLR3, 7, and 9 is crucial for TLR signaling. J Cell Biol 2007, 177:265-275.
10. Qi R., Hoose S., Schreiter J., Sawant K.V., Lamb R., Ranjith-Kumar C.T., et al. Secretion of the human Toll-like receptor 3 ectodomain is affected by single nucleotide polymorphisms and regulated by Unc93b1. J Biol Chem 2010, 285:36635-36644.
11. McBride S., Hoebe K., Georgel P., Janssen E. Cell-associated double-stranded RNA enhances antitumor activity through the production of type I IFN. J Immunol 2006, 177:6122-6128.
12. Kariko K., Ni H., Capodici J., Lamphier M., Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 2004, 279:12542-12550.
13. Kariko K., Buckstein M., Ni H., Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005, 23:165-175.
14. Ishii K.J., Akira S. TLR ignores methylated RNA?. Immunity 2005, 23:111-113.
15. Kariko K., Bhuyan P., Capodici J., Weissman D. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J Immunol 2004, 172:6545-6549.
16. Kleinman M.E., Yamada K., Takeda A., Chandrasekaran V., Nozaki M., Baffi J.Z., et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008, 452:591-597.
17. Oshiumi H., Matsumoto M., Funami K., Akazawa T., Seya T. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. Nat Immunol 2003, 4:161-167.
18. Tatematsu M., Ishii A., Oshiumi H., Horiuchi M., Inagaki F., Seya T., et al. A molecular mechanism for Toll-IL-1 receptor domain-containing adaptor molecule-1-mediated IRF-3 activation. J Biol Chem 2010, 285:20128-20136.
19. Honda K., Takaoka A., Taniguchi T. Type I interferon gene induction by the interferon regulatory factor family of transcription factors. Immunity 2006, 25:349-360.
20. Sasai M., Tatematsu M., Oshiumi H., Funami K., Matsumoto M., Hatakeyama S., et al. Direct binding of TRAF2 and TRAF6 to TICAM-1/TRIF adaptor participates in activation of the Toll-like receptor 3/4 pathway. Mol Immunol 2010, 47:1283-1291.
21. Siednienko J., Halle A., Nagpal K., Golenbock D.T., Miggin S.M. TLR3-mediated IFN-beta gene induction is negatively regulated by the TLR adaptor MyD88 adaptor-like. Eur J Immunol 2010, 40:3150-3160.
22. Meylan E., Burns K., Hofmann K., Blancheteau V., Martinon F., Kelliher M., et al. RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation. Nat Immunol 2004, 5:503-507.
23. Cusson-Hermance N., Khurana S., Lee T.H., Fitzgerald K.A., Kelliher M.A. Rip1 mediates the Trif-dependent toll-like receptor 3- and 4-induced NF-{kappa}B activation but does not contribute to interferon regulatory factor 3 activation. J Biol Chem 2005, 280:36560-36566.
24. Sen G.C., Sarkar S.N. Transcriptional signaling by double-stranded RNA: role of TLR3. Cytokine Growth Factor Rev 2005, 16:1-14.
25. Jiang Z., Zamanian-Daryoush M., Nie H., Silva A.M., Williams B.R., Li X. Poly(I-C)-induced Toll-like receptor 3 (TLR3)-mediated activation of NFkappa B and MAP kinase is through an interleukin-1 receptor-associated kinase (IRAK)-independent pathway employing the signaling components TLR3-TRAF6-TAK1-TAB2-PKR. J Biol Chem 2003, 278:16713-16719.
26. Chang M., Jin W., Sun S.C. Peli1 facilitates TRIF-dependent Toll-like receptor signaling and proinflammatory cytokine production. Nat Immunol 2009, 10:1089-1095.
27. Shim J.H., Xiao C., Paschal A.E., Bailey S.T., Rao P., Hayden M.S., et al. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev 2005, 19:2668-2681.
28. Banerjee A., Gugasyan R., McMahon M., Gerondakis S. Diverse Toll-like receptors utilize Tpl2 to activate extracellular signal-regulated kinase (ERK) in hemopoietic cells. Proc Natl Acad Sci USA 2006, 103:3274-3279.
29. Kaiser W.J., Offermann M.K. Apoptosis induced by the toll-like receptor adaptor TRIF is dependent on its receptor interacting protein homotypic interaction motif. J Immunol 2005, 174:4942-4952.
30. Cho Y.S., Challa S., Moquin D., Genga R., Ray T.D., Guildford M., et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 2009, 137:1112-1123.
31. Zhang D.W., Shao J., Lin J., Zhang N., Lu B.J., Lin S.C., et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 2009, 325:332-336.
32. Festjens N., Vanden Berghe T., Cornelis S., Vandenabeele P. RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Differ 2007, 14:400-410.
33. Netea M.G., van der Meer J.W. Immunodeficiency and genetic defects of pattern-recognition receptors. N Engl J Med 2011, 364:60-70.
34. Bousfiha A., Picard C., Boisson-Dupuis S., Zhang S.Y., Bustamante J., Puel A., et al. Primary immunodeficiencies of protective immunity to primary infections. Clin Immunol 2010, 135:204-209.
35. Schulz O., Diebold S.S., Chen M., Naslund T.I., Nolte M.A., Alexopoulou L., et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005, 433:887-892.
36. Frleta D., Yu C.I., Klechevsky E., Flamar A.L., Zurawski G., Banchereau J., et al. Influenza virus and poly(I:C) inhibit MHC class I-restricted presentation of cell-associated antigens derived from infected dead cells captured by human dendritic cells. J Immunol 2009, 182:2766-2776.
37. Salaun B., Coste I., Rissoan M.C., Lebecque S.J., Renno T. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 2006, 176:4894-4901.
38. Akazawa T., Ebihara T., Okuno M., Okuda Y., Shingai M., Tsujimura K., et al. Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc Natl Acad Sci USA 2007, 104:252-257.
39. Galli R., Starace D., Busa R., Angelini D.F., Paone A., De Cesaris P., et al. TLR stimulation of prostate tumor cells induces chemokine-mediated recruitment of specific immune cell types. J Immunol 2010, 184:6658-6669.
40. Shojaei H., Oberg H.H., Juricke M., Marischen L., Kunz M., Mundhenke C., et al. Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gammadelta T cells. Cancer Res 2009, 69:8710-8717.
41. Cavassani K.A., Ishii M., Wen H., Schaller M.A., Lincoln P.M., Lukacs N.W., et al. TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events. J Exp Med 2008, 205:2609-2621.
42. Ritter M., Mennerich D., Weith A., Seither P. Characterization of Toll-like receptors in primary lung epithelial cells: strong impact of the TLR3 ligand poly(I:C) on the regulation of Toll-like receptors, adaptor proteins and inflammatory response. J Inflamm (Lond) 2005, 2:16.
43. Wang Q., Nagarkar D.R., Bowman E.R., Schneider D., Gosangi B., Lei J., et al. Role of double-stranded RNA pattern recognition receptors in rhinovirus-induced airway epithelial cell responses. J Immunol 2009, 183:6989-6997.
44. Rudd B.D., Burstein E., Duckett C.S., Li X., Lukacs N.W. Differential role for TLR3 in respiratory syncytial virus-induced chemokine expression. J Virol 2005, 79:3350-3357.
45. Rudd B.D., Smit J.J., Flavell R.A., Alexopoulou L., Schaller M.A., Gruber A., et al. Deletion of TLR3 alters the pulmonary immune environment and mucus production during respiratory syncytial virus infection. J Immunol 2006, 176:1937-1942.
46. Koff J.L., Shao M.X., Ueki I.F., Nadel J.A. Multiple TLRs activate EGFR via a signaling cascade to produce innate immune responses in airway epithelium. Am J Physiol Lung Cell Mol Physiol 2008, 294:L1068-1075.
47. Yu M., Lam J., Rada B., Leto T.L., Levine S.J. Double-stranded RNA induces shedding of the 34-kDa soluble TNFR1 from human airway epithelial cells via TLR3-TRIF-RIP1-dependent signaling: roles for dual oxidase 2- and caspase-dependent pathways. J Immunol 2011, 186:1180-1188.
48. Torres D., Dieudonne A., Ryffel B., Vilain E., Si-Tahar M., Pichavant M., et al. Double-stranded RNA exacerbates pulmonary allergic reaction through TLR3: implication of airway epithelium and dendritic cells. J Immunol 2010, 185:451-459.
49. Joshi A.D., Schaller M.A., Lukacs N.W., Kunkel S.L., Hogaboam C.M. TLR3 modulates immunopathology during a Schistosoma mansoni egg-driven Th2 response in the lung. Eur J Immunol 2008, 38:3436-3449.
50. Okun E., Griffioen K., Barak B., Roberts N.J., Castro K., Pita M.A., et al. Toll-like receptor 3 inhibits memory retention and constrains adult hippocampal neurogenesis. Proc Natl Acad Sci USA 2010, 107:15625-15630.
51. Saito T., Gale M. Differential recognition of double-stranded RNA by RIG-I-like receptors in antiviral immunity. J Exp Med 2008, 205:1523-1527.
52. Satoh T., Kato H., Kumagai Y., Yoneyama M., Sato S., Matsushita K., et al. LGP2 is a positive regulator of RIG-I- and MDA5-mediated antiviral responses. Proc Natl Acad Sci USA 2010, 107:1512-1517.
53. Onoguchi K., Yoneyama M., Fujita T. Retinoic acid-inducible gene-I-like receptors. J Interferon Cytokine Res 2011, 31:27-31.
54. Cui S., Eisenacher K., Kirchhofer A., Brzozka K., Lammens A., Lammens K., et al. The C-terminal regulatory domain is the RNA 5'-triphosphate sensor of RIG-I. Mol Cell 2008, 29:169-179.
55. Myong S., Cui S., Cornish P.V., Kirchhofer A., Gack M.U., Jung J.U., et al. Cytosolic viral sensor RIG-I is a 5'-triphosphate-dependent translocase on double-stranded RNA. Science 2009, 323:1070-1074.
56. Saito T., Hirai R., Loo Y.M., Owen D., Johnson C.L., Sinha S.C., et al. Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. Proc Natl Acad Sci USA 2007, 104:582-587.
57. Hayakawa S., Shiratori S., Yamato H., Kameyama T., Kitatsuji C., Kashigi F., et al. ZAPS is a potent stimulator of signaling mediated by the RNA helicase RIG-I during antiviral responses. Nat Immunol 2011, 12:37-44.
58. Wang P., Arjona A., Zhang Y., Sultana H., Dai J., Yang L., et al. Caspase-12 controls West Nile virus infection via the viral RNA receptor RIG-I. Nat Immunol 2010, 11:912-919.
59. Fujita T. A nonself RNA pattern: tri-p to panhandle. Immunity 2009, 31:4-5.
60. Rehwinkel J., Reis e Sousa C. RIGorous detection: exposing virus through RNA sensing. Science 2010, 327:284-286.
61. Takahasi K., Yoneyama M., Nishihori T., Hirai R., Kumeta H., Narita R., et al. Nonself RNA-sensing mechanism of RIG-I helicase and activation of antiviral immune responses. Mol Cell 2008, 29:428-440.
62. Schlee M., Roth A., Hornung V., Hagmann C.A., Wimmenauer V., Barchet W., et al. Recognition of 5′ triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity 2009, 31:25-34.
63. Fujita T. Virology. Sensing viral RNA amid your own. Science 2006, 314:935-936.
64. Schmidt A., Schwerd T., Hamm W., Hellmuth J.C., Cui S., Wenzel M., et al. 5′-Triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I. Proc Natl Acad Sci USA 2009, 106:12067-12072.
65. Rehwinkel J., Tan C.P., Goubau D., Schulz O., Pichlmair A., Bier K., et al. RIG-I detects viral genomic RNA during negative-strand RNA virus infection. Cell 2010, 140:397-408.
66. Wang Y., Ludwig J., Schuberth C., Goldeck M., Schlee M., Li H., et al. Structural and functional insights into 5′-ppp RNA pattern recognition by the innate immune receptor RIG-I. Nat Struct Mol Biol 2010, 17:781-787.
67. Yoneyama M., Fujita T. RNA recognition and signal transduction by RIG-I-like receptors. Immunol Rev 2009, 227:54-65.
68. Seth R.B., Sun L., Ea C.K., Chen Z.J. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 2005, 122:669-682.
69. Moore C.B., Bergstralh D.T., Duncan J.A., Lei Y., Morrison T.E., Zimmermann A.G., et al. NLRX1 is a regulator of mitochondrial antiviral immunity. Nature 2008, 451:573-577.
70. Baril M., Racine M.E., Penin F., Lamarre D. MAVS dimer is a crucial signaling component of innate immunity and the target of hepatitis C virus NS3/4A protease. J Virol 2009, 83:1299-1311.
71. You F., Sun H., Zhou X., Sun W., Liang S., Zhai Z., et al. PCBP2 mediates degradation of the adaptor MAVS via the HECT ubiquitin ligase AIP4. Nat Immunol 2009, 10:1300-1308.
72. Vitour D., Dabo S., Ahmadi Pour M., Vilasco M., Vidalain P.O., Jacob Y., et al. Polo-like kinase 1 (PLK1) regulates interferon (IFN) induction by MAVS. J Biol Chem 2009, 284:21797-21809.
73. Michallet M.C., Meylan E., Ermolaeva M.A., Vazquez J., Rebsamen M., Curran J., et al. TRADD protein is an essential component of the RIG-like helicase antiviral pathway. Immunity 2008, 28:651-661.
74. Tang E.D., Wang C.Y. TRAF5 is a downstream target of MAVS in antiviral innate immune signaling. PLoS One 2010, 5:e9172.
75. Sasai M., Shingai M., Funami K., Yoneyama M., Fujita T., Matsumoto M., et al. NAK-associated protein 1 participates in both the TLR3 and the cytoplasmic pathways in type I IFN induction. J Immunol 2006, 177:8676-8683.
76. Kato H., Sato S., Yoneyama M., Yamamoto M., Uematsu S., Matsui K., et al. Cell type-specific involvement of RIG-I in antiviral response. Immunity 2005, 23:19-28.
77. McCartney S., Vermi W., Gilfillan S., Cella M., Murphy T.L., Schreiber R.D., et al. Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. J Exp Med 2009, 206:2967-2976.
78. Wang Y., Cella M., Gilfillan S., Colonna M. Cutting edge: polyinosinic:polycytidylic acid boosts the generation of memory CD8 T cells through melanoma differentiation-associated protein 5 expressed in stromal cells. J Immunol 2010, 184:2751-2755.
79. Besch R., Poeck H., Hohenauer T., Senft D., Hacker G., Berking C., et al. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest 2009, 119:2399-2411.
80. Poeck H., Besch R., Maihoefer C., Renn M., Tormo D., Morskaya S.S., et al. 5′-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med 2008, 14:1256-1263.
81. Kubler K., Gehrke N., Riemann S., Bohnert V., Zillinger T., Hartmann E., et al. Targeted activation of RNA helicase retinoic acid-inducible gene-I induces proimmunogenic apoptosis of human ovarian cancer cells. Cancer Res 2010, 70:5293-5304.
82. Ou C.C., Hsu S.C., Hsieh Y.H., Tsou W.L., Chuang T.C., Liu J.Y., et al. Downregulation of HER2 by RIG1 involves the PI3K/Akt pathway in ovarian cancer cells. Carcinogenesis 2008, 29:299-306.
83. Schroder K., Tschopp J. The inflammasomes. Cell 2010, 140:821-832.
84. Franchi L., Eigenbrod T., Munoz-Planillo R., Nunez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 2009, 10:241-247.
85. Kanneganti T.D., Body-Malapel M., Amer A., Park J.H., Whitfield J., Franchi L., et al. Critical role for cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA. J Biol Chem 2006, 281:36560-36568.
86. Owen D.M., Gale M. Fighting the flu with inflammasome signaling. Immunity 2009, 30:476-478.
87. Allen I.C., Scull M.A., Moore C.B., Holl E.K., McElvania-TeKippe E., Taxman D.J., et al. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity 2009, 30:556-565.
88. Schroder K., Zhou R., Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger?. Science 2010, 327:296-300.
89. Ghiringhelli F., Apetoh L., Tesniere A., Aymeric L., Ma Y., Ortiz C., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009, 15:1170-1178.
90. Ichinohe T., Lee H.K., Ogura Y., Flavell R., Iwasaki A. Inflammasome recognition of influenza virus is essential for adaptive immune responses. J Exp Med 2009, 206:79-87.
91. Thomas P.G., Dash P., Aldridge J.R., Ellebedy A.H., Reynolds C., Funk A.J., et al. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity 2009, 30:566-575.
92. Ichinohe T., Pang I.K., Iwasaki A. Influenza virus activates inflammasomes via its intracellular M2 ion channel. Nat Immunol 2010, 11:404-410.
93. Poeck H., Bscheider M., Gross O., Finger K., Roth S., Rebsamen M., et al. Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production. Nat Immunol 2010, 11:63-69.
94. Nicodemus C.F., Berek J.S. TLR3 agonists as immunotherapeutic agents. Immunotherapy 2010, 2:137-140.
95. Kanzler H., Barrat F.J., Hessel E.M., Coffman R.L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007, 13:552-559.
96. Stahl-Hennig C., Eisenblatter M., Jasny E., Rzehak T., Tenner-Racz K., Trumpfheller C., et al. Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog 2009, 5:e1000373.
97. Trumpfheller C., Caskey M., Nchinda G., Longhi M.P., Mizenina O., Huang Y., et al. The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci USA 2008, 105:2574-2579.
98. Longhi M.P., Trumpfheller C., Idoyaga J., Caskey M., Matos I., Kluger C., et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 2009, 206:1589-1602.
99. Gibbert K., Dietze K.K., Zelinskyy G., Lang K.S., Barchet W., Kirschning C.J., et al. Polyinosinic-polycytidylic acid treatment of Friend retrovirus-infected mice improves functional properties of virus-specific T cells and prevents virus-induced disease. J Immunol 2010, 185:6179-6189.
100. Trapp S., Derby N.R., Singer R., Shaw A., Williams V.G., Turville S.G., et al. Double-stranded RNA analog poly(I:C) inhibits human immunodeficiency virus amplification in dendritic cells via type I interferon-mediated activation of APOBEC3G. J Virol 2009, 83:884-895.
101. Gowen B.B., Wong M.H., Jung K.H., Sanders A.B., Mitchell W.M., Alexopoulou L., et al. TLR3 is essential for the induction of protective immunity against Punta Toro Virus infection by the double-stranded RNA (dsRNA), poly(I:C12U), but not Poly(I:C): differential recognition of synthetic dsRNA molecules. J Immunol 2007, 178:5200-5208.
102. Carter W.A., Strayer D.R., Brodsky I., Lewin M., Pellegrino M.G., Einck L., et al. Clinical, immunological, and virological effects of ampligen, a mismatched double-stranded RNA, in patients with AIDS or AIDS-related complex. Lancet 1987, 1:1286-1292.
103. Ichinohe T., Ainai A., Ami Y., Nagata N., Iwata N., Kawaguchi A., et al. Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus. J Med Virol 2010, 82:1754-1761.
104. Zhu X., Fallert-Junecko B.A., Fujita M., Ueda R., Kohanbash G., Kastenhuber E.R., et al. Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners. Cancer Immunol Immunother 2010, 59:140-149.
105. Zhu X., Nishimura F., Sasaki K., Fujita M., Dusak J.E., Eguchi J., et al. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med 2007, 5:10.
106. Okada H., Kalinski P., Ueda R., Hoji A., Kohanbash G., Donegan T.E., et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011, 30:225-231.
107. Olsen N.J., Stein C.M. New drugs for rheumatoid arthritis. N Engl J Med 2004, 350:2167-2179.
108. Mertens M., Singh J.A. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 2009, 36:1118-1125.
109. Gabay C., Lamacchia C., Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 2010, 6:232-241.
110. Dinarello C.A. Anti-inflammatory agents: present and future. Cell 2010, 140:935-950.
111. Larsen C.M., Faulenbach M., Vaag A., Volund A., Ehses J.A., Seifert B., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007, 356:1517-1526.
112. Larsen C.M., Faulenbach M., Vaag A., Ehses J.A., Donath M.Y., Mandrup-Poulsen T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009, 32:1663-1668.
113. So A., De Meulemeester M., Pikhlak A., Yucel A.E., Richard D., Murphy V., et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010, 62:3064-3076.
114. Terkeltaub R., Sundy J.S., Schumacher H.R., Murphy F., Bookbinder S., Biedermann S., et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009, 68:1613-1617.
115. Abbate A., Salloum F.N., Vecile E., Das A., Hoke N.N., Straino S., et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 2008, 117:2670-2683.
116. Emsley H.C., Smith C.J., Georgiou R.F., Vail A., Hopkins S.J., Rothwell N.J., et al. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry 2005, 76:1366-1372.
117. Tarhini A.A., Millward M., Mainwaring P., Kefford R., Logan T., Pavlick A., et al. A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer 2009, 115:859-868.
118. Abulafia D.P., de Rivero Vaccari J.P., Lozano J.D., Lotocki G., Keane R.W., Dietrich W.D. Inhibition of the inflammasome complex reduces the inflammatory response after thromboembolic stroke in mice. J Cereb Blood Flow Metab 2009, 29:534-544.
119. Ross J., Brough D., Gibson R.M., Loddick S.A., Rothwell N.J. A selective, non-peptide caspase-1 inhibitor, VRT-018858, markedly reduces brain damage induced by transient ischemia in the rat. Neuropharmacology 2007, 53:638-642.
120. Mitroulis I., Skendros P., Ritis K. Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome. Eur J Intern Med 2010, 21:157-163.